Anke Hemmerling MD, PhD, MPH

Lecturer, Intedisciplinary MPH program
  • MD - Humboldt University Berlin, Germany. 1999
  • PhD - Medical Sciences, Humboldt University Berlin, Germany. 2003
  • MPH - University of California at Berkeley, USA. 2004
  • PH 292(12): Core Seminar Interdisciplinary Program
  • GHS 208: UCSF Global Health Sciences Masters Program: Women's Health and Empowerment
Research Interests: 
  • HIV/AIDS prevention
  • Sexual and reproductive health
  • Safe motherhood
  • Global health
  • Family Planning and Infertility
  • Multipurpose prevention technologies for reproductive health
Research Description: 

In her research, Dr. Hemmerling combines the approaches from her training in clinical medicine and in public health, with a special focus on global women's health and sexually transmitted infections. Her research has included work on medication abortion with mifepristone, the use of misoprostol for postpartum hemorrhage in developing countries, the scope of infertility in developing countries, and the use of live biotherapeutic products such as lactobacilli for the prevention of genital and sexually transmitted infections.

Current Projects: 

Anke Hemmerling is a Project Director at the UCSF Bixby Center for Global Reproductive Health, implementing studies of live biotherapeutic products for the prevention of HIV and other genital infections in women. In addition, she is the Co-Chair of the Education Committee at the UC Global Health Institute Center of Expertise in Women's Health and Empowerment, and a faculty member at the School of Public Health at the University of California, Berkeley. At UCSF and UCB, she is mentoring and teaching medical students, graduate students and post-doctoral students in several educational programs, including the UCSF Infectious Disease Research and Training program (IDRTP), the UCSF Global Health Masters Program and the UCB Interdisciplinary MPH program. Dr. Hemmerling also serves as the Deputy Director of the Coalition Advancing Multipurpose Innovations (CAMI), the secretariat of the Initiative for Multipurpose Prevention Technologies for Reproductive Health. She has gained additional experience in global health research and practice during clinical training in Latin America, and as a UCB Bixby Fellow of Population, Family Planning and International Health, and as a Director of Special Health Projects at Venture Strategies for Health and Development.

Selected Publications: 

Harrison PF, Hemmerling A, Romano J, Whaley KJ, Young Holt B.Developing multipurpose reproductive health technologies: an integrated strategy. AIDS Res Treat. 2013. Epub 2013 Feb 28.

Ngugi BM, Hemmerling A, Bukusi EA, Kikuvi G, Gikunju J, Shiboski S, Fredricks DN, Cohen CR. Effects of bacterial vaginosis-associated bacteria and sexual intercourse on vaginal colonization with the probiotic Lactobacillus crispatus CTV-05. Sex Transm Dis. 2011 Nov;38(11):1020-7.

Hemmerling A, Cohen CR. Probiotics: the potential for a live microbicide to prevent HIV. J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):e98-101.

Decker M, Hemmerling A, Lankoande F. Women front and center: the opportunities of involving women in participatory health research worldwide. J Womens Health (Larchmt). 2010 Nov;19(11):2109-14.

Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Foster-Rosales A, Cohen CR. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex Transm Dis. 2010 Dec;37(12):745-50.

Hemmerling A, Harrison W, Schroeder A et al. Phase 1 Dose-ranging Safety Trial of Lactobacillus crispatus CTV-05 (LACTIN-V) for the Prevention of Bacterial Vaginosis. Sex Transm Dis. 2009 Sep;36(9):564-9.

Hemmerling A, Potts M, Walsh J, Young-Holt B, Whaley K, Stefanski DA. Lime Juice as a Candidate Microbicide? An Open-Label Safety Trial of 10% and 20% Lime Juice Used Vaginally. Journal of Women's Health 2007; 16 (7): 1041-1051.

Potts M, Hemmerling A. The worldwide burden of postpartum haemorrhage: Policy development where inaction is lethal. Int J Gynaecol Obstet. 2006 Nov;94 Suppl 2:S116-21.

Miller S, Lehman T, Campbell M, Hemmerling A, Anderson SB, Rodriguez H, Gonzalez WV, Cordero M, Calderon V.Misoprostol and declining abortion-related morbidity in Santo Domingo, Dominican Republic: a temporal association. BJOG. 2005 Sep;112(9):1291-6.

Hemmerling A, Siedentopf F, Kentenich H. Emotional impact and acceptability of medical abortion with mifepristone: a German experience. J Psychosom Obstet Gynaecol. 2005 Mar;26(1):23-31.

Profile Updated: July 18, 2013